Levintow Sara N, Reading Stephanie R, Noshad Sina, Mayer Sophie E, Wiener Catherine, Eledath Bassim, Exter Jason, Brookhart M Alan
NoviSci, Inc., Durham, NC, USA.
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Clin Epidemiol. 2022 Jun 1;14:737-748. doi: 10.2147/CLEP.S361258. eCollection 2022.
Routine monitoring of low-density lipoprotein cholesterol (LDL-C) identifies patients who may benefit from modifying lipid-lowering therapies (LLT). However, the extent to which LDL-C testing is occurring in clinical practice is unclear, specifically among patients hospitalized for a myocardial infarction (MI).
Using US commercial claims data, we identified patients with an incident MI hospitalization between 01/01/2008-03/31/2019. LDL-C testing was assessed in the year before admission (pre-MI) and the year after discharge (post-MI). Changes in LDL-C testing were evaluated using a Poisson model fit to pre-MI rates and extrapolated to the post-MI period. We predicted LDL-C testing rates if no MI had occurred (ie, based on pre-MI trends) and estimated rate differences and ratios (contrasting observed vs predicted rates).
Overall, 389,367 patients were hospitalized for their first MI during the study period. In the month following discharge, 9% received LDL-C testing, increasing to 27% at 3 months and 52% at 12 months. Mean rates (tests per 1000 patients per month) in the pre- and post-MI periods were 51.9 (95% CI: 51.7, 52.1) and 84.4 (95% CI: 84.1, 84.6), respectively. Over 12 months post-MI, observed rates were higher than predicted rates; the maximum rate difference was 66 tests per 1000 patients in month 2 (rate ratio 2.2), stabilizing at a difference of 15-20 (ratio 1.2-1.3) for months 6-12.
Although LDL-C testing increased following MI hospitalization, rates remained lower than recommended by clinical guidelines. This highlights a potential gap in care, where increased LDL-C testing after MI may provide opportunities for LLT modification and decrease risk of subsequent cardiovascular events.
常规监测低密度脂蛋白胆固醇(LDL-C)可识别可能从调整降脂治疗(LLT)中获益的患者。然而,LDL-C检测在临床实践中的开展程度尚不清楚,尤其是在因心肌梗死(MI)住院的患者中。
利用美国商业保险理赔数据,我们识别出了2008年1月1日至2019年3月31日期间首次因MI住院的患者。在入院前一年(MI前)和出院后一年(MI后)评估LDL-C检测情况。使用泊松模型对MI前的检测率进行拟合,并外推至MI后时期,评估LDL-C检测的变化。我们预测了如果未发生MI时的LDL-C检测率(即基于MI前的趋势),并估计了率差和率比(对比观察到的与预测的检测率)。
总体而言,在研究期间有389,367例患者首次因MI住院。出院后第一个月,9%的患者接受了LDL-C检测,3个月时增至27%,12个月时增至52%。MI前和MI后时期的平均检测率(每1000例患者每月的检测次数)分别为51.9(95%CI:51.7,52.1)和84.4(95%CI:84.1,84.6)。在MI后的12个月内,观察到的检测率高于预测率;最大率差为第2个月时每1000例患者66次检测(率比2.2),在第6至12个月稳定在15 - 20次的差值(率比1.2 - 1.3)。
尽管MI住院后LDL-C检测有所增加,但检测率仍低于临床指南的推荐水平。这凸显了一个潜在的护理差距,即MI后增加LDL-C检测可能为调整LLT提供机会,并降低后续心血管事件的风险。